Race and Prostate Cancer: Genomic Landscape

Overview

Journal Nat Rev Urol

Specialty Urology

Date 2022 Aug 9

PMID 35945369

Authors

Camilo Arenas-Gallo

Jude Owiredu

Ilon Weinstein

Patrick Lewicki

Spyridon P Basourakos

Randy Vince Jr

Bashir Al Hussein Al Awamlh

Fredrick R Schumacher

Daniel E Spratt

Christopher E Barbieri

Jonathan E Shoag

Affiliations

Soon will be listed here.

Abstract

In the past 20 years, new insights into the genomic pathogenesis of prostate cancer have been provided. Large-scale integrative genomics approaches enabled researchers to characterize the genetic and epigenetic landscape of prostate cancer and to define different molecular subclasses based on the combination of genetic alterations, gene expression patterns and methylation profiles. Several molecular drivers of prostate cancer have been identified, some of which are different in men of different races. However, the extent to which genomics can explain racial disparities in prostate cancer outcomes is unclear. Future collaborative genomic studies overcoming the underrepresentation of non-white patients and other minority populations are essential.

Citing Articles

Disparities in Cancer and Cardiovascular Disease Mortality Among Asian Americans Diagnosed with Urologic Cancer.

Deng Z, Li M, Li J, Jung M, Batai K, Moore J J Racial Ethn Health Disparities. 2025; .

PMID: 40067651 DOI: 10.1007/s40615-025-02354-4.

Current landscape of exosomal non-coding RNAs in prostate cancer: Modulators and biomarkers.

Li Y, Tang X, Wang B, Chen M, Zheng J, Chang K Noncoding RNA Res. 2024; 9(4):1351-1362.

PMID: 39247145 PMC: 11380467. DOI: 10.1016/j.ncrna.2024.07.003.

Synergistic Strategies for Castration-Resistant Prostate Cancer: Targeting AR-V7, Exploring Natural Compounds, and Optimizing FDA-Approved Therapies.

Rahman M, Akter K, Ahmed K, Maharub Hossain Fahim M, Aktary N, Park M Cancers (Basel). 2024; 16(16).

PMID: 39199550 PMC: 11352813. DOI: 10.3390/cancers16162777.

Association between patient ethnicity and prostate cancer diagnosis following a prostate-specific antigen test: a cohort study of 730,000 men in primary care in the UK.

Down L, Barlow M, Bailey S, Mounce L, Merriel S, Watson J BMC Med. 2024; 22(1):82.

PMID: 38424555 PMC: 10905783. DOI: 10.1186/s12916-024-03283-5.

Evaluation of Survival Outcomes Among Black and White Patients with Metastatic Castration-resistant Prostate Cancer: A Systematic Review and Meta-analysis.

Yang J, Xiong X, Zheng W, Liao X, Xu H, Yang L Eur Urol Open Sci. 2024; 61:10-17.

PMID: 38384441 PMC: 10879936. DOI: 10.1016/j.euros.2024.01.004.

References

Siegel R, Miller K, Fuchs H, Jemal A . Cancer Statistics, 2021. CA Cancer J Clin. 2021; 71(1):7-33. DOI: 10.3322/caac.21654. View

Grasso C, Wu Y, Robinson D, Cao X, Dhanasekaran S, Khan A . The mutational landscape of lethal castration-resistant prostate cancer. Nature. 2012; 487(7406):239-43. PMC: 3396711. DOI: 10.1038/nature11125. View

Taylor B, Schultz N, Hieronymus H, Gopalan A, Xiao Y, Carver B . Integrative genomic profiling of human prostate cancer. Cancer Cell. 2010; 18(1):11-22. PMC: 3198787. DOI: 10.1016/j.ccr.2010.05.026. View

Mersha T, Abebe T . Self-reported race/ethnicity in the age of genomic research: its potential impact on understanding health disparities. Hum Genomics. 2015; 9:1. PMC: 4307746. DOI: 10.1186/s40246-014-0023-x. View

Banda Y, Kvale M, Hoffmann T, Hesselson S, Ranatunga D, Tang H . Characterizing Race/Ethnicity and Genetic Ancestry for 100,000 Subjects in the Genetic Epidemiology Research on Adult Health and Aging (GERA) Cohort. Genetics. 2015; 200(4):1285-95. PMC: 4574246. DOI: 10.1534/genetics.115.178616. View

Stopsack K, Nandakumar S, Arora K, Nguyen B, Vasselman S, Nweji B . Differences in Prostate Cancer Genomes by Self-reported Race: Contributions of Genetic Ancestry, Modifiable Cancer Risk Factors, and Clinical Factors. Clin Cancer Res. 2021; 28(2):318-326. PMC: 8776579. DOI: 10.1158/1078-0432.CCR-21-2577. View

Li J, Xu C, Lee H, Ren S, Zi X, Zhang Z . A genomic and epigenomic atlas of prostate cancer in Asian populations. Nature. 2020; 580(7801):93-99. DOI: 10.1038/s41586-020-2135-x. View

Koga Y, Song H, Chalmers Z, Newberg J, Kim E, Carrot-Zhang J . Genomic Profiling of Prostate Cancers from Men with African and European Ancestry. Clin Cancer Res. 2020; 26(17):4651-4660. PMC: 7597977. DOI: 10.1158/1078-0432.CCR-19-4112. View

Shoag J, Barbieri C . Clinical variability and molecular heterogeneity in prostate cancer. Asian J Androl. 2016; 18(4):543-8. PMC: 4955177. DOI: 10.4103/1008-682X.178852. View

10.

Tomlins S, Rhodes D, Perner S, Dhanasekaran S, Mehra R, Sun X . Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science. 2005; 310(5748):644-8. DOI: 10.1126/science.1117679. View

11.

Tomlins S, Bjartell A, Chinnaiyan A, Jenster G, Nam R, Rubin M . ETS gene fusions in prostate cancer: from discovery to daily clinical practice. Eur Urol. 2009; 56(2):275-86. DOI: 10.1016/j.eururo.2009.04.036. View

12.

Mehra R, Tomlins S, Yu J, Cao X, Wang L, Menon A . Characterization of TMPRSS2-ETS gene aberrations in androgen-independent metastatic prostate cancer. Cancer Res. 2008; 68(10):3584-90. PMC: 2677168. DOI: 10.1158/0008-5472.CAN-07-6154. View

13.

Attard G, Swennenhuis J, Olmos D, Reid A, Vickers E, AHern R . Characterization of ERG, AR and PTEN gene status in circulating tumor cells from patients with castration-resistant prostate cancer. Cancer Res. 2009; 69(7):2912-8. DOI: 10.1158/0008-5472.CAN-08-3667. View

14.

Perner S, Demichelis F, Beroukhim R, Schmidt F, Mosquera J, Setlur S . TMPRSS2:ERG fusion-associated deletions provide insight into the heterogeneity of prostate cancer. Cancer Res. 2006; 66(17):8337-41. DOI: 10.1158/0008-5472.CAN-06-1482. View

15.

Tomlins S, Mehra R, Rhodes D, Smith L, Roulston D, Helgeson B . TMPRSS2:ETV4 gene fusions define a third molecular subtype of prostate cancer. Cancer Res. 2006; 66(7):3396-400. DOI: 10.1158/0008-5472.CAN-06-0168. View

16.

Helgeson B, Tomlins S, Shah N, Laxman B, Cao Q, Prensner J . Characterization of TMPRSS2:ETV5 and SLC45A3:ETV5 gene fusions in prostate cancer. Cancer Res. 2008; 68(1):73-80. DOI: 10.1158/0008-5472.CAN-07-5352. View

17.

Magi-Galluzzi C, Tsusuki T, Elson P, Simmerman K, LaFargue C, Esgueva R . TMPRSS2-ERG gene fusion prevalence and class are significantly different in prostate cancer of Caucasian, African-American and Japanese patients. Prostate. 2010; 71(5):489-97. DOI: 10.1002/pros.21265. View

18.

Minner S, Enodien M, Sirma H, Luebke A, Krohn A, Mayer P . ERG status is unrelated to PSA recurrence in radically operated prostate cancer in the absence of antihormonal therapy. Clin Cancer Res. 2011; 17(18):5878-88. DOI: 10.1158/1078-0432.CCR-11-1251. View

19.

Park K, Tomlins S, Mudaliar K, Chiu Y, Esgueva R, Mehra R . Antibody-based detection of ERG rearrangement-positive prostate cancer. Neoplasia. 2010; 12(7):590-8. PMC: 2907585. DOI: 10.1593/neo.10726. View

20.

Schumacher F, Basourakos S, Lewicki P, Vince R, Spratt D, Barbieri C . Race and Genetic Alterations in Prostate Cancer. JCO Precis Oncol. 2021; 5. PMC: 8563071. DOI: 10.1200/PO.21.00324. View